Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Celcuity Inc.

Market Cap 4.28B 3.73B 3.44B 3.23B 6.05B 403B 6.09B 40.9B 15.88B 199B 16.06B 15.72B 689B P/E 2026 *
-21.8x
P/E 2027 * -187x
Enterprise Value 4.28B 3.73B 3.44B 3.23B 6.05B 403B 6.09B 40.9B 15.88B 199B 16.06B 15.72B 689B EV / Sales 2026 *
102x
EV / Sales 2027 * 11.2x
Free-Float
89.97%
Yield 2026 *
-
Yield 2027 * -
1 day-0.33%
1 week-1.93%
Current month-33.96%
1 month-33.61%
3 months-22.00%
6 months-11.50%
Current year-12.01%
1 week 82.55
Extreme 82.5536
90.61
1 month 82.55
Extreme 82.5536
142.82
Current year 82.55
Extreme 82.5536
151.02
1 year 11.28
Extreme 11.275
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 01/01/2012
Chief Executive Officer 64 01/01/2012
Director of Finance/CFO 59 01/07/2017
Director TitleAgeSince
Chairman 64 01/01/2012
Director/Board Member 64 01/01/2012
Director/Board Member 67 01/02/2014
Date Insider Type Main position Quantity % Market Cap.
06-10Don

Director

-28,096 0.0607%
06-10Don

Director

-25,006 0.0540%
06-05Free

Director

1,530 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%-1.93%+643.10%+717.13% 4.28B
+0.89%-1.79%+62.64%+113.72% 54.44B
+4.60%+5.82%+56.35%+43.04% 45.8B
-1.44%+1.51%-12.94%-19.24% 22.98B
-2.69%-0.95%-3.68%+379.00% 20.76B
+3.22%+2.94%+24.02%-35.05% 16.25B
+0.61%+1.17%+16.83%-38.00% 15.34B
-1.01%-2.97%+27.42%+171.92% 13.05B
+3.07%+5.43%+21.37% - 12.37B
+4.95%+13.49%+121.11%+249.05% 12.47B
Average +1.19%+1.78%+95.62%+175.73% 21.78B
Weighted average by Cap. +1.46%+1.32%+51.20%+111.28%

Financials

2026 *2027 *
Net sales 42.08M 36.66M 33.8M 31.79M 59.47M 3.97B 59.89M 402M 156M 1.95B 158M 155M 6.77B 383M 334M 308M 289M 541M 36.09B 545M 3.66B 1.42B 17.79B 1.44B 1.41B 61.65B
Net income -218M -190M -175M -164M -308M -20.52B -310M -2.08B -808M -10.11B -817M -800M -35.05B -34.95M -30.45M -28.07M -26.4M -49.39M -3.29B -49.74M -334M -130M -1.62B -131M -128M -5.63B
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
18/06/26 87.76 $ -0.33% 2,126,823
17/06/26 88.05 $ +0.84% 1,212,278
16/06/26 87.32 $ -1.04% 906,054
15/06/26 88.24 $ -0.35% 1,142,410
12/06/26 88.55 $ -1.05% 1,532,972
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
87.76USD
Average target price
161.09USD
Spread / Average Target
+83.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!